



coordinated care™

Endocrine and Metabolic Agents: Metabolic Modifiers- Adenosine Deaminase SCID Treatment Agents- Injectable (Revcovi®)

WA.PHAR.75 Endocrine and Metabolic Agents: Metabolic Modifiers – Adenosine Deaminase SCID Treatment Agents - Injectable (Revcovi®)

Effective Date: July 1, 2019

Background:

Enzyme replacement therapy for adenosine deaminase severe combined immune deficiency (ADA-SCID) using elapegamase-lvlr, marketed as Revcovi®, is managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs
J3590	Unclassified biologics

History

Date	Action and Summary of Changes
01/26/2021	<ul style="list-style-type: none"> Re-added Codes C9399, J3490, & J3590. Removed JCODE J1428 (wrong drug).
07/01/2020	<ul style="list-style-type: none"> Added disclaimer regarding the HCPCS Code. Removed JCODES C9399, J3490, & J3590. Added JCODE: J1428